International Journal of Infectious Diseases
Volume 13, Issue 1 , Pages 24-36 , January 2009

The economic impact of aspergillosis: analysis of hospital expenditures across patient subgroups

  • Kuo B. Tong

      Affiliations

    • Quorum Consulting, Inc., 222 Kearny Street, 10th Floor, San Francisco, CA 94108, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 415 835 0190; fax: +1 415 835 0199.
    • ,
  • Christopher J. Lau

      Affiliations

    • Quorum Consulting, Inc., 222 Kearny Street, 10th Floor, San Francisco, CA 94108, USA
    • ,
  • Kirsten Murtagh

      Affiliations

    • Quorum Consulting, Inc., 222 Kearny Street, 10th Floor, San Francisco, CA 94108, USA
    • ,
  • Andrew J. Layton

      Affiliations

    • Quorum Consulting, Inc., 222 Kearny Street, 10th Floor, San Francisco, CA 94108, USA
    • ,
  • Raafat Seifeldin

      Affiliations

    • Astellas Pharma US Inc., Deerfield, IL, USA

Received 21 August 2006 ,Revised 20 November 2007 ,Accepted 16 February 2008.

References 

  1. Stevens DA, Kan VL, Judson MA, Morrison VA, Dummer S, Denning DW, et al. Practice guidelines for diseases caused by Aspergillus. Clin Infect Dis. 2003;30:696–709
  2. Soubani AO, Chandrasekar PH. The clinical spectrum of pulmonary aspergillosis. Chest. 2002;121:1988–1999
  3. Lin S, Schranz J, Teutsch SM. Aspergillosis case–fatality rate: systematic review of the literature. Clin Infect Dis. 2003;32:358–366
  4. Singh N. The current management of infectious diseases in the liver transplant recipient. Clin Liver Dis. 2000;4:657–673ix
  5. Morgan J, Wannemuehler KA, Marr KA, Hadley S, Kontoyiannis DP, Walsh TJ, et al. Incidence of invasive aspergillosis following hematopoietic stem cell and solid organ transplantation: interim results of a prospective multicenter surveillance program. Med Mycol. 2005;43(Suppl 1):S49–S58
  6. Groll AH, Shah PM, Mentzel C, Schneider M, Just-Nuebling G, Huebner K. Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. J Infect. 1996;33:23–32
  7. Warnock DW. Trends in the epidemiology of invasive fungal infections. Nippon Ishinkin Gakkai Zasshi. 2007;48:1–12
  8. Denning DW. Invasive aspergillosis. Clin Infect Dis. 1998;26:781–805
  9. Van Gool R. The cost of treating systemic fungal infections. Drugs. 2001;61(Suppl 1):49–56
  10. Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis. 2002;34:909–917
  11. Marr KA, Seidel K, Slavin MA, Bowden RA, Schoch HG, Flowers MD, et al. Prolonged fluconazole prophylaxis increases long term survival and protects against candidiasis deaths for allogeneic marrow transplants. Evidence-based Oncology. 2001;2:17–18
  12. Wingard JR. Antifungal chemoprophylaxis after blood and marrow transplantation. Clin Infect Dis. 2002;34:1386–1390
  13. Wilson LS, Reyes CM, Stolpman M, Speckman J, Allen K, Beney J. The direct cost and incidence of systemic fungal infections. Value Health. 2002;5:26–34
  14. Health Care Utilization Project. Nationwide Inpatient Sample, Year 2003. Washington, DC: Department of Health and Human Services, U.S. Public Health Service, Agency for Healthcare Research and Quality; 2003.
  15. Medicare Provider Analysis and Review. Fiscal year 2003. Baltimore, MD: CMS; 2003.
  16. US Department of Commerce. United States Census Bureau On-line. Available at: www.census.gov (accessed April 2008).
  17. Patterson TF, Kirkpatrick WR, White M, Hiemenz JW, Wingard JR, Dupont B, et al. Invasive aspergillosis: disease spectrum, treatment practices, and outcomes. Medicine (Baltimore). 2000;79:250–260
  18. Alangaden GJ, Wahiduzzaman M, Chandrasekar PH Bone Marrow Transplant Group. Aspergillosis: the most common community-acquired pneumonia with Gram-negative bacilli as copathogens in stem cell transplant recipients with graft-versus-host disease. Clin Infect Dis. 2002;35:659–664
  19. Calvo V, Borro JM, Morales P, Morcillo A, Vicente R, Tarrazona V, et al. Antifungal prophylaxis during the early postoperative period of lung transplantation. Chest. 1999;115:1301–1304
  20. Singh N, Avery RK, Munoz P, Pruett TL, Alexander B, Jacobs R, et al. Trends in risk profiles for and mortality associated with invasive aspergillosis among liver transplant recipients. Clin Infect Dis. 2003;36:46–52
  21. Wingard JR. Changing times: patient characteristics and fungal epidemiology. In: Fungal infections following BMT: re-examining current approaches. Presented at the Annual Meeting of the American Society for Blood and Marrow Transplantation, Keystone, Colorado, USA, 2003.
  22. Kistemann T, Huneburg H, Exner M, Vacata V, Engelhart S. Role of increased environmental Aspergillus exposure for patients with chronic obstructive pulmonary disease (COPD) treated with corticosteroids in an intensive care unit. Int J Hyg Environ Health. 2002;204:347–351
  23. Pelz RK, Lipsett PA, Swoboda SM, Diener-West M, Powe NR, Brower RG, et al. Candida infections: outcome and attributable ICU costs in critically ill patients. J Intensive Care Med. 2000;15:255–261
  24. Vandewoude K, Blot S, Benoit D, Depuydt P, Vogelaers D, Colardyn F. Invasive aspergillosis in critically ill patients: analysis of risk factors for acquisition and mortality. Acta Clin Belg. 2004;59:251–257
  25. Sharma S, Nadrous HF, Peters SG, Tefferi A, Litzow MR, Aubry MC, et al. Pulmonary complications in adult blood and marrow transplant recipients: autopsy findings. Chest. 2005;128:1385–1392
  26. Jansen JP, Kern WV, Cornely OA, Karthaus M, Ruhnke M, Ullmann AJ, et al. Economic evaluation of voriconazole versus conventional amphotericin B in the treatment of invasive aspergillosis in Germany. Value Health. 2006;9:12–23

PII: S1201-9712(08)00092-1

doi: 10.1016/j.ijid.2008.02.013

International Journal of Infectious Diseases
Volume 13, Issue 1 , Pages 24-36 , January 2009

Article Tools